Year: 2026
Type: review
Abstract: Prostate cancer is the most common cancer diagnosed in men. Metastatic castration-resistant prostate cancer (mCRPC) is associated with significant morbidity and mortality. The last decades have seen the introduction of multiple new therapeutic agents, such as androgen receptor pathway inhibitors, PARP inhibitors, new cytotoxic agents, and radioligand therapies. Further advancements are being made with immunotherapy utilising new molecular targets. As these treatments move earlier in the treatment pathway, determining the optimal treatment sequencing becomes the challenge. This review aimed to highlight established treatments, recent developments, and promising therapies in mCRPC.
Source: Frontiers in Endocrinology
Authors: Ilesha Ewart, Manreet Randhawa
Institution: Beatson West of Scotland Cancer Centre
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7221183698